Mekinist

Summary

Name(s) Target Manufacturer Status
Mekinist, trametinib MAP2K1, MAP2K2 GlaxoSmithKline FDA approved for: Melanoma, BRAF V600E Mutated, Melanoma, BRAF V600K Mutated

Clinical Trials

Trial Drug Status Phase
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. [NCT01682083] Mekinist, Tafinlar Recruiting Phase 3
A Single Cohort Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Exploratory Translational Research, and Safety Endpoints of Preoperative Treatment of GSK2118436 in Subjects With BRAF V600E or V600K Mutation-positive Metastatic Melanoma to th... [NCT01978236] Mekinist, Tafinlar Not yet recruiting Phase 2
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery [NCT01701037] Mekinist, Tafinlar Recruiting Phase 2
NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors [NCT01827384] Afinitor, Carboplatin, MK-1775, Mekinist, Temodar, veliparib Recruiting Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma [NCT01979523] GSK2141795, Mekinist Recruiting Phase 2
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain [NCT02039947] Mekinist, Tafinlar Recruiting Phase 2
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [NCT01726738] Mekinist, Tafinlar Recruiting Phase 2
GSK1120212 Rollover Study [NCT01376310] Abraxane, Afinitor, Alimta, Carboplatin, Gemzar, Mekinist, Tarceva, Taxotere Recruiting Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma [NCT01941927] GSK2141795, Mekinist Recruiting Phase 2
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor [NCT01619774] Mekinist, Tafinlar Recruiting Phase 2
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery [NCT01989585] ABT-263, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022) [NCT02130466] Pembrolizumab, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma [NCT02110355] AMG 232, Mekinist, Tafinlar Not yet recruiting Phase 1/Phase 2
Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery [NCT01970956] ABT-263, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone [NCT02027961] MEDI4736, Mekinist, Tafinlar Recruiting Phase 1/Phase 2
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients [NCT02143050] Mekinist, Metformin, Tafinlar Not yet recruiting Phase 1/Phase 2
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies [NCT01725100] Mekinist Recruiting Phase 1
Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery [NCT01940809] Mekinist, Tafinlar, Yervoy Recruiting Phase 1
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases [NCT02015117] Mekinist Recruiting Phase 1
Trametinib in Treating Patients With Advanced Cancer and Hepatic Dysfunction [NCT02070549] Mekinist Recruiting Phase 1
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors [NCT01231594] Mekinist, Tafinlar Recruiting Phase 1
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma [NCT02138292] Mekinist, digoxin Not yet recruiting Phase 1
Safety, Pharmacokinetics (PK) of AKT and MEK Combination [NCT01138085] GSK2141795, Mekinist Recruiting Phase 1
Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery [NCT02097225] AT13387, Mekinist, Tafinlar Recruiting Phase 1
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations [NCT02124772] Mekinist Not yet recruiting Phase 1
A Study of LY2875358 in Participants With Advanced Cancer [NCT01287546] LY2875358, Mekinist, Tarceva Recruiting Phase 1
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma [NCT01767454] Mekinist, Tafinlar, Yervoy Recruiting Phase 1
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors [NCT02065063] Mekinist, PD-0332991 Not yet recruiting Phase 1
#